OncoBeta® GmbH, a commercial-stage medical device company specialized in innovative epidermal radioisotope therapies announced that it has formalized it’s manufacturing partnership with ANSTO.

Following the completion of all regulatory approvals, ANSTO will produce OncoBeta’s novel RheniumSCT® therapeutic for the treatment of non-melanoma skin cancer. OncoBeta® GmbH expects to launch Rhenium-SCT® by late 2021.

To read more please visit:

ANSTO is the new production partner of OncoBeta® GmbH in Australia-ANSTO

Source: ANSTO